GraniteShares Advisors LLC Lowers Holdings in Edwards Lifesciences Co. (NYSE:EW)

GraniteShares Advisors LLC cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 17.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,354 shares of the medical research company’s stock after selling 2,132 shares during the period. GraniteShares Advisors LLC’s holdings in Edwards Lifesciences were worth $767,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in EW. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $555,939,000. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares in the last quarter. Finally, Seilern Investment Management Ltd purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $109,490,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

EW opened at $71.46 on Wednesday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $72.78 and its 200-day simple moving average is $70.18. The company has a market capitalization of $42.15 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 in the last three months. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent research reports. Barclays increased their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, The Goldman Sachs Group increased their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.